You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Navigating the Patient Journey for LA SCCHN: A Look at Treatments for Today and Tomorrow

  • Authors: Nabil F. Saba, MD, FACP; Robert Ferris, MD, PhD; Nancy Y. Lee, MD, FASTRO
  • CME / ABIM MOC / CE Released: 10/19/2023
  • Valid for credit through: 10/19/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    Nurses - 1.00 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    Pharmacists - 1.00 Knowledge-based ACPE (0.100 CEUs)

    IPCE - 1.0 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, radiation oncologists, head and neck surgeons, oncology nurses, oncology nurse practitioners and physician assistants, oncology pharmacists, and other clinicians who provide care for patients with LA SCCHN.

The goal of this activity is for learners to be better able to make informed clinical treatment decisions for patients with LA SCCHN throughout their care journey.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Pathophysiology of LA SCCHN
    • Clinical evidence evaluating treatment approaches for patients with LA SCCHN
  • Have greater competence related to
    • Creating patient-centric treatment plans for patients throughout the spectrum of LA SCCHN
  • Demonstrate greater confidence in their ability to
    • Coordinate with the interdisciplinary team to optimize quality of life in patients with LA SCCHN


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


  • Nabil F. Saba, MD, FACP

    Professor and Vice Chair, Hematology and Medical Oncology  
    The Lynne and Howard Halpern Chair in Head and Neck Cancer Research 
    Director, H&N Oncology 
    Co-Director H&N CA Multidisciplinary Program  
    Winship Cancer Institute  
    Emory University  
    Atlanta, Georgia 


    The opinions expressed are those of Dr Saba and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Saba’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

    Nabil F. Saba, MD, FACP, has the following relevant financial relationships:
    Consultant or advisor for: Adagene; Aduro Biotech, Inc.; AstraZeneca; Astex Pharmaceuticals; Aveo Oncology; BioNTech; Bristol Myers Squibb; Celldex Therapeutics; Coherus BioSciences; Cornerstone Pharmaceuticals; Cue Biopharma; Eisai, Inc; EMD Serono, Inc.; Exelixis, Inc.; Faron Pharmaceutical; Flamingo Pharma; Fulgent Pharma; GlaxoSmithKline; Imugene; Infinity Pharmaceuticals, Inc.; INOVIO Pharmaceuticals; Kura Oncology, Inc.; Merck & Co., Inc.; Nanobiotix; Pfizer Inc.; Seagen Inc.; Surface Oncology; Tosk Inc.; Vaccinex Inc.​
    Research funding from: Bristol Myers Squibb Company; Exelixis, Inc.


  • Robert Ferris, MD, PhD

    Director, UPMC Hillman Cancer Center  
    Hillman Professor of Oncology 
    UPMC Senior Vice President for Oncology Programs 
    Associate Vice-Chancellor for Cancer Research 
    University of Pittsburgh School of Medicine 
    Pittsburgh, Pennsylvania 


    Robert Ferris, MD, PhD, has the following relevant financial relationships: 
    Consultant or advisor for: Adagene Incorporated; Aduro Biotech, Inc; Bicara Therapeutics, Inc; Bristol Myers Squibb Company; Brooklyn Immunotherapeutics LLC; Catenion; Coherus BioSciences, Inc; Eisai Europe Limited; EMD Serono; Everest Clinical Research Corporation; F. Hoffmann-La Roche Ltd; Federation Bio, Inc; Genocea Biosciences, Inc; Genmab; Hookipa Biotech GmbH; Instil Bio, Inc; Kowa Research Institute, Inc; Lifescience Dynamics Limited; MacroGenics, Inc; MeiraGTx, LLC; Merck & Co., Inc.; Merus N.V; Mirati Therapeutics, Inc; Nanobiotix; Novartis Pharmaceutical; Novasenta; Numab Therapeutics AG; OncoCyte Corporation; Pfizer Inc.; PPD Development, L.P.; Rakuten Medical, Inc; Sanofi; Seagen, Inc; SIRPant Immunotherapeutics, Inc; Vir Biotechnology, Inc; Zymeworks, Inc
    Research funding from: Astra-Zeneca/MedImmune Inc.; Bristol Myers Squibb Company; Merck & Co., Inc.; Novasenta; Tesaro
    Other: Mirror Biologics Inc: Data Safety Monitoring Board

  • Nancy Y. Lee, MD, FASTRO

    Vice Chair, Experimental Therapeutics 
    Department of Radiation Oncology 
    Service Chief, Head and Neck Radiation Oncology 
    Service Chief, Proton Therapy 
    Memorial Sloan Kettering Cancer Center 
    New York, New York 


    Nancy Y. Lee, MD, FASTRO, has no relevant financial relationships.


  • Amy Furedy, RN, OCN

    Medical Education Director, Medscape, LLC


    Amy Furedy, RN, OCN, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

    For Nurses

  • Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-23-369-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Navigating the Patient Journey for LA SCCHN: A Look at Treatments for Today and Tomorrow

Authors: Nabil F. Saba, MD, FACP; Robert Ferris, MD, PhD; Nancy Y. Lee, MD, FASTROFaculty and Disclosures

CME / ABIM MOC / CE Released: 10/19/2023

Valid for credit through: 10/19/2024, 11:59 PM EST


Educational Impact Challenge

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

  • Print